Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

Original Research



Role of ormeloxifene, a selective estrogen receptor modulator in heavy menstrual bleeding (abnormal uterine bleeding)

Yashodhara Gaur, Hemlata Parashar, Swati Jain.

Abstract
Background: During womenís reproductive years, heavy menstrual bleeding (HMB) (abnormal uterine bleeding; AUB) is the most common reason for abnormal vaginal bleeding. Evidence is lacking for medical management of HMB (AUB). Ormeloxifene a selective estrogen receptor modulator (SERM) has emerged as one of the safe and effective candidates for the management of HMB (AUB).

Objectives: The objectives of this study were to study the efficacy and safety of SERM, ormeloxifene in the treatment of HMB (AUB).

Material and Methods: A total of 65 patients of HMB (AUB) were studied in the Department of Obstetrics and Gynecology, GR Medical College, Gwalior, from September 2011 to December 2013. Detailed history, clinical examination, and laboratory investigations including hemoglobin percentage, blood sugar, papís smear, transvaginal ultrasonography, and dilatation and curettage were recorded for each patient. Tablet containing 60 mg of ormeloxifene was given for twice a week for first 12 weeks then 60 mg once a week for next 12 weeks. All the patients were followed up for 6 months till the 6 months.

Results: Maximum patients had age between 31 and 40 years (46.5%). The most common parity was one to three (53.4%). Most of the cases complained of menorrhagia (41.8%). Majority of the cases showed proliferative endometrium (49.18%). Of 65, 5 could not be followed up due to various reasons. At 12 weeks of treatment, most of the cycles exceeded their pretreatment cycle length; improvement in duration of blood flow and dysmenorrhea (from 76.7% case to 19%) was observed; spotting and passage of clots were not observed in 58% by 12 weeks and 96% patients by 24 weeks. Most frequent side effects complained by patients were prolonged cycle beyond 35 days (50%).

Conclusion: Ormeloxifene is a good choice for the treatment of HMB (AUB) due to its excellent efficacy and safety profile.

Key words: Dysmenorrhea; Endometrium; Ormeloxifene; Selective Estrogen Receptor Modulator



Share this Article


Advertisement
Oxidants and Antioxidants in Medical Science

SUBMIT YOUR ARTICLE NOW


ScopeMed.com
BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMedģ Information Services.